Biotech | August 10, 2021
INNOVIO QoQ revenues down for the period ended June 30, 2021
Company working on COVID vaccine INO 4800
Company working on COVID vaccine INO 4800
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
